A detailed history of Price T Rowe Associates Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 48,927 shares of SNDX stock, worth $639,965. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,927
Previous 48,198 1.51%
Holding current value
$639,965
Previous $990,000 4.85%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.93 - $24.81 $13,070 - $18,086
729 Added 1.51%
48,927 $942,000
Q2 2024

Aug 14, 2024

BUY
$18.82 - $23.79 $69,408 - $87,737
3,688 Added 8.29%
48,198 $990,000
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $359,569 - $448,230
18,243 Added 69.45%
44,510 $1.06 Million
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $21,151 - $40,241
1,857 Added 7.61%
26,267 $568,000
Q3 2023

Nov 14, 2023

BUY
$14.52 - $21.77 $21,358 - $32,023
1,471 Added 6.41%
24,410 $355,000
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $223,976 - $258,238
11,575 Added 101.86%
22,939 $481,000
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $41,320 - $57,960
2,000 Added 21.36%
11,364 $241,000
Q4 2022

Feb 14, 2023

BUY
$20.64 - $26.24 $19,298 - $24,534
935 Added 11.09%
9,364 $238,000
Q3 2022

Nov 14, 2022

BUY
$18.51 - $24.79 $156,020 - $208,954
8,429 New
8,429 $203,000
Q4 2021

Feb 14, 2022

SELL
$15.23 - $22.47 $7.86 Million - $11.6 Million
-516,098 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$13.87 - $19.8 $1.33 Million - $1.89 Million
95,678 Added 22.76%
516,098 $9.86 Million
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $249,571 - $468,272
-18,597 Reduced 4.24%
420,420 $7.22 Million
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $5.16 Million - $6.58 Million
267,578 Added 156.08%
439,017 $9.82 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $2.59 Million - $4.53 Million
171,439 New
171,439 $3.81 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $740M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.